Purpose: From the published literature, we identified 23 germ line sequence variants in 17 genes from hypothesis-generating studies that were associated with prognosis of head and neck cancer, including sequence variants of DNA repair (ERCC1, ERCC4, ERCC5, MSH2, XPA, ERCC2, XRCC1, XRCC3), DNA methylation (DNMT3B), cell cycle and proliferation (CCND1, TP53), xenobiotic metabolism (GSTM1, GSTT1, CYP2D6), metastatic -potential (MMP3), immunologic (CTLA4), and growth factor pathways (FGFR4). The purpose of this study was to validate the role of these 23 sequence variants for overall (OS) and disease-free survival (DFS) in a large, comprehensive, well-annotated data set of patients with head and neck cancer.
Introduction
Carcinomas of the oral cavity, pharynx, and larynx are referred to as head and neck cancers; together they account for 2% to 3% of all newly diagnosed cancers in North America (1, 2) . Most head and neck cancers are squamous cell carcinomas (SCC) and they vary according to their degree of differentiation to well, moderate, and poor carcinomas. Some anatomic subsites appear to have better prognosis, but this may be more related to earlier symptoms leading to diagnosis at an earlier stage. Between 33% and 50% of head and neck cancers are early diagnosed at stages I and II (3, 4) . In the 1990s, vast majority of patients had a history of smoking and alcohol consumption that was considered to be a significant cofactor. However, increasing evidence has recently documented human papilloma virus (HPV) as a cause of specific subsets of head and neck SCCs (HNSCC; ref. 5 ). Treatment of early-stage head and neck cancers is usually based on a multidisciplinary approach including radiation therapy and/or surgery, depending on the extent and location of the tumor. However, results with such treatments have not been completely satisfactory due to high mortality and early recurrence of disease. For all stages combined, about 83% of persons with head and neck cancers survive 1 year after diagnosis. The 5-year and 10-year relative survival rates are 61% and 50%, respectively (2).
The long-term survival of patients with head and neck cancer has improved only moderately, and a leading cause of morbidity in such patients is still recurrent disease.
Germ line genetic sequence variants (GSV) have become increasingly studied as potential prognostic or predictive markers of outcome in a variety of cancers including head and neck cancer (6) , lung cancer (7), esophageal cancer (8) , and breast cancer (9) . An argument has been made that, in addition to tumor molecular prognostic factors, GSVs may play key roles in driving the carcinogenesis process and thus are useful in stratifying different biologic pathways driving the eventual cancer, which then correlates with the susceptibility of the cancer to standard therapies. Identifying these GSVs may therefore increase the accuracy and validity of outcome prediction models.
Recently, we reviewed the published literature on studies of GSVs as prognostic markers (6) . We discovered that practically all the studies were hypothesis generating, with virtually no replication studies. Lack of replication in large, well-annotated data sets has become a major obstacle in separating true-from false-positive associations. We seek to fill this knowledge gap by validating 23 GSVs previously described to be associated with head and neck cancer outcomes [either overall survival (OS) or disease-free survival (DFS); ref. 6 ) in 17 key genes of the following pathways: DNA repair, cell-cycle control, xenobiotic metabolism, inflammatory, immune, growth factor, and developmental/DNA methylation pathways in a well-annotated clinical trial of 531 patients with early-stage radiation-treated head and neck cancer (10) .
Materials and Methods

Study population
All 531 patients with stage I and II radiation-treated head and neck cancers were from an NCI-Canada-funded randomized secondary prevention trial of alpha-tocopherol/ beta-carotene supplementation from 1994 to 2000 at 5 different radiation treatment centers in Qu ebec, Canada. Study subjects were histologically documented as SCCs of the tongue, gum, mouth, oropharynx, hypopharynx, pharynx, or larynx. Although one of the primary objectives was to assess whether the intervention would reduce the incidence of second primary cancers, results indicated no such improvement (10) . The Institutional Review Board of each participating center, at Centre Hospitalier Universitaire de Qu ebec (CHUQ) and at University Health Network (UHN) approved the study protocol. Participant consent, inclusion criteria, and other study design details have been described previously (11) (12) (13) .
Data collection and follow-up
Baseline data collection was completed before patients were randomly assigned. Demographic information, smoking history, alcohol use, and clinical data were available for all participants. Follow-up information was obtained at predetermined times: immediately and 1 month after radiation therapy ended, every 6 months during the 3 years following the end of radiation therapy, and then once a year until the end of the study. Medical notes and hospital records were requested for all important health events and hospitalizations during follow-up. During each visit, the radiation oncologists assessed the recurrence of the initial tumor and the occurrence of any second primary cancer. In addition to ensure complete ascertainment of deaths, record linkage with the Qu ebec mortality files was conducted using the unique Qu ebec health insurance identifier from enrollment until December 31, 2006 , for all but 10 participants who did not consent to this record linkage. Death certificates were obtained for all participants who died.
Sequence variant selection
A literature review was previously published by several of our authors, where we identified 24 sequence variations from 22 studies that were found to be associated with head and neck cancer outcome and prognosis (6) . All studies were case series or cohort observational studies or subsets of cohort, case-control, or randomized controlled studies. Study populations were predominantly Caucasian or Asian. The chosen candidate sequence variants and their respective pathways are shown in Table 1 . One sequence variant was not genotyped because the minor allele frequency was extremely low in Caucasians, which was the predominant population in our validation patients (6).
Genotyping
Genomic DNA was extracted from peripheral blood lymphocytes using QIAamp DNA Blood Maxi Kit (Qiagen) according to the manufacturer's recommendations. We aimed to genotype as many of the 23 sequence variants using iPLEX Gold assay on the MassARRAYÒ Platform System (Sequenom). However, 12 sequence variants were genotyped using this method that maximized multiplex-PCR amplification and universal-reaction condition
Translational Relevance
Genetic sequence variants (GSV) may be useful clinical predictors of outcome in head and neck cancers. However, published studies that have evaluated the role of GSV in head and neck cancer outcomes have all been hypothesis-generating studies. No GSV markers have been properly validated. As the first validation-focused study, we evaluated a pristine large cohort of patients that were originally part of a clinical trial to validate an extensive set of GSV for overall and disease-free survival. We showed that none of these prior published GSV biomarkers were validated for overall or disease-free survival in our data set, after adjustment for multiple comparisons. We conclude that candidate-based evaluations of GSVs for prognosis of head and neck cancers have a very limited role. Hypothesis-free, genome-wide evaluations may have an improved chance of identifying clinically useful GSV should they exist. efficiencies. We used other conventional genotyping methods such as real-time PCR-based allelic discrimination and single-nucleotide primer extension assay for the remaining 11 sequence variants. Human predesigned TaqMan SNP genotyping assays on ABI 7900 HT fast real-time PCR system (Applied Biosystems) were used for 7 sequence variants. The remaining 4 sequence variants were genotyped using the SNaPshot Multiplex System (Applied Biosystems). All genotyping assays followed the manufacturer's protocols. For quality control, we included positive and negative controls and blinded duplicate samples for each run. Moreover, raw genotyped data were rechecked by 2 independent researchers for the call rate and genotyping quality. The detail list of the sequence variants and their respective genotyping assays are listed in Table 1 .
Statistical methods
Two separate outcomes were studied: OS and DFS. For OS, follow-up time was calculated from the time of randomization until the date of last visit (for the 10 participants who had not consented to record linkage), the date of death, or December 31, 2006. For DFS, follow-up time was counted from randomization until the first occurrence before June 30, 2003, of cancer recurrence, the data of death, or the date of last visit. Survival rates were estimated by using the Kaplan-Meier estimator. For each sequence variants, allele and genotype frequencies were calculated, minor allele (lowest frequency) and major allele (highest frequency) were determined, and departures from HardyWeinberg equilibrium (HWE) were tested using the Pearson c 2 test. Cox proportional hazards (CPH) models were used to test for associations between the sequence variants and OS and DFS.
We based our baseline multivariate models on clinical survival analyses (13) and included both standard clinical and some newer epidemiologic variables of significance: (i) For OS, we generated comprehensive models adjusted for age, smoking, alcohol intake, body mass index (BMI), Charlson comorbidity index, Karnofsky performance status, cancer site, and cancer stage; and (ii) For DFS, the comprehensive models were adjusted for age, smoking, BMI, Karnofsky performance status, cancer site, and cancer stage. All models were stratified according to randomization arm (i.e., supplement or placebo).
At first, we used the additive model of genetic inheritance to maximize power for the screening analysis. We then extended the analysis to include other genetic model of inheritance such as codominant, recessive, and dominant models to further confirm and explore the associations. Adjusted HRs (aHR) and their 95% confidence intervals (95% CI) for OS and DFS were reported. Pairwise interactions in between sequence variants were investigated using stratified comprehensive CPH models and additive genetic model.
In our study, Wald test was used for all the genetic models of inheritance including additive, recessive, dominant, and codominant. To account for multiple comparisons, we used a practical P value cutoff point of 0.01 (14) ; P values 0.05 were considered to have nominal significance and potential association. This P value was preset as practical because it balanced study power of our data set with stringency of adjustment for multiple comparisons. For the significant interactions, we conducted subgroup analyses to describe the relationship between the sequence variants and the outcomes across different genotypes. All significant tests conducted for CPH models were Wald tests. All statistical tests were 2-sided and were conducted using the SAS software (version 9.3, SAS Institute Inc.) and the R software (version 2.4.0, R Development Core Team).
Results
Demographics
The baseline personal and clinical characteristics of the study participants are shown in Table 2 . In all, 330 (62%) patients had stage I and 201 (38%) patients had stage II disease. The most frequent tumor location was the larynx (n ¼ 443; 83%) and the remaining (n ¼ 88; 17%) were in the oral cavity and pharynx. If we only considered patients who had not experienced the outcome, the median follow-up time for OS and DFS were 9.21 and 5.36 years, respectively. Five-year OS rate was 77% (95% CI, 0.73-0.80); 312 patients were alive at December 2006, the last date of follow-up for survival. Five-year DFS rate was 64% (95% CI, 0.60-0.68); 333 patients were alive and free of disease by June 2003.
Genotyping analyses
Details of genotype frequency, minor allele frequency, and HWE of each sequence variants are shown in Table 3 . No significant deviation from HWE was observed for any of the sequence variants.
Association between sequence variants and OS
Significant association of CTLA4:A49G and XRCC1: Arg399Gln sequence variants with OS were found in different genetic model of inheritance. For CTLA4:A49G, the aHR for the additive model was 1.32 (95% CI, 1.08-1.62; P ¼ 0.01) for each G allele compared with the reference (no G allele ¼ AA genotype). For the codominant model, when we compared the GG genotype with AA, the aHR was 1.79 (Continued on the following page) (15) . For XRCC1:Arg399Gln, the aHR for the additive model was 1.28 (95% CI, 1.05-1.57; P ¼ 0.02) for each Gln variant compared with the reference of no variant alleles (i.e., Arg/ Arg). Although the results were also significant, the direction of association was opposite that of prior studies (16) , and thus these results were not replicated. Details of the sequence variants, their genetic models, and association with OS are shown in Table 4 .
Association between sequence variants and DFS
We also examined the association of sequence variants with DFS and found borderline significant associations of ERCC2:Lys751Gln and TP53:Arg72Pro sequence variants with DFS. For ERCC2:Lys751Gln, the aHR for the additive model was 0.80 (95% CI, 0.64-1.00; P ¼ 0.05) for each Gln variant allele compared with the reference of no variant alleles (i.e., Lys/Lys). For TP53:Arg72Pro, the aHR for the additive model was 1.28 (95% CI, 1.02-1.60; P ¼ 0.03) for each Pro allele, when compared with the reference (Arg/Arg). Details of the polymorphic variants associated with DFS are shown in Table 5 .
Exploratory analyses: interactions between significant sequence variants
We next evaluated potential interactions between the significant sequence variants for OS and DFS, namely, CTLA4:A49G, ERCC2:Lys751Gln, and TP53:Arg72Pro and each of the other 23 sequence variants assessed in this study for both OS and DFS. None of the remaining sequence variants had significant interactions with CTLA4:A49G and interactions with TP53:Arg72Pro were statistically significant. In the case of XRCC1:Arg399Gln for OS, there were 2 significant interactions (i) between XRCC1:Arg399Gln and ERCC5:His1104Asp (P interaction ¼ 0.01); and (ii) between XRCC1:Arg399Gln and MMP3:À1612insA (P interaction ¼ 0.01). For DFS, there is a significant interaction, between ERCC2:Lys751Gln and XPA:5 0 UTR (P interaction ¼ 0.04), another DNA repair pathway sequence variant. The details of these interactions are shown in Table 6 .
Discussion
In a recent review (17) , a number of concerns with the current state of the literature were identified in regard to GSVs and cancer outcome association studies. These concerns included (i) an overrepresentation of hypothesisgenerating studies, without adequate focus on validation studies; (ii) the selection of a small number of candidate sequence variants, without consideration of prior published work of additionally relevant sequence variants; (iii) the need for systematic discovery validation studies; and (iv) a multitude of studies with small samples sizes. Head and neck cancers are a heterogeneous group of tumors with high rate of early recurrence, development of secondary primary cancers (18) , and mortality. In the present study, we used a large data set of more than 500 patients with head and neck cancer (which is among the largest data sets that have both biologic germ line material and long-term prospectively collected outcome data) to validate a comprehensive set of 23 sequence variants where each individual or combination of sequence variants had been previously described to have significant associations with head and neck cancer outcomes (i.e., OS and DFS) in the published literature. For OS, we found the CTLA4:A49G and XRCC1: Arg339Gln had significant results in the opposite direction to prior published literature. For DFS, ERCC2:Lys751Gln and TP53:Arg72Pro were marginally associated with DFS, prior to but not after adjustment for multiple comparisons. We also observed a potential interaction of XRCC1:Arg399Gln with ERCC5:His110Asp and MMP3:À1612insA in relation to OS and of ERCC2:Lys751Gln with another DNA repair pathway sequence variants, XPA:5 0 UTR, in relation to DFS. There are several important implications of our results, which are based on carefully collected outcome data in the context of a clinical trial. First, the vast majority of prior positive findings were not replicated in our data set. Reasons for this include different stage distribution of patients, different distribution of patient demographics (age, gender, ethnicity, and smoking prevalence), different treatments, and different distribution of anatomic subsites between studies. One could always devise an argument to suggest that the original study's vitamin supplementation may be interfering with potential sequence variants-outcome associations. In addition, prior results may have been false positives; a multistep discovery-validation approach for main effect analyses of clinical outcomes would reduce such false positivity similar to what has become standard in cancer risk analyses. Second, the lack of replication of these studies that contained mostly a few sequence variants assessed, in addition to a suggestion of a potential DNA repair pathway interaction of XRCC1 with ERCC5 and ERCC2 with XPA sequence variants suggest that newer approaches such as comprehensive pathway analyses, or even genome-wide association studies, may yield results that have improved chances to replicate across multiple data sets. In particular, the sequence variants-drug, sequence variants-radiotherapy interaction effects on outcome, or sequence variants associated with secondary primary cancer are promising areas of future research (17, 18) . Sequence variants in the CTLA4 gene have been reported to be associated with susceptibility to various cancers (19) (20) (21) (22) . Here, we found patients carrying the variant G allele of CTLA4:A49G have worse OS than patients carrying the AA wild-type genotype, contrary to prior publication. The variant G allele has a functional effect on the expression level of CTLA4 (23, 24) . Because CTLA4 acts specifically as a negative regulator of T-cell activation, it is plausible that the variant G allele might contribute to interindividual differences in inflammatory and immune responses that lead to a biologic subtype that is more aggressive and therefore has worse outcomes. At the amino acid level (p.Thr17Ala), the substitution of alanine for threonine occurs in a highly conserved position and changes glycosylation in one of two possible sites (25) . Moreover, patients with GG genotype in comparison with the AA genotype have been shown to have increased mRNA and protein expression (26) . The connection between the functional change in CTLA4 and its impact of survival bears further study.
Polymorphisms in several DNA repair pathway genes have been identified and studied extensively in relationship with cancers. XRCC1:Arg399Gln, a sequence variant in DNA repair pathway gene, has been reported to increase the risk of developing HNSCC (27) . We found that Arg/Gln carriers have significantly reduced OS when compared with Arg/Arg carriers. Carriers of the variant Gln allele have been shown to have higher level of DNA adducts (28) and to be a great risk of ionizing radiation sensitivity (29) and tobaccorelated DNA damage (30, 31) . Moreover, this amino acid substitution (Arg>Gln) produces significant conformational changes at BRTC1 domain (from amino acid 314 to 403) that may be critical for protein-protein interactions (32), thus absence or impairment repair may cause genomic instability and cancer occurrence or outcome. Indeed, we found interactions between XRCC1:Arg399Gln and another DNA repair GSV ERCC5:His110Asp and an inflammatory gene sequence variant MMP3:À1612insA. Both ERCC5:His110Asp and MMP3:À1612insA sequence variants are known to be associated with head and neck cancer outcome (33, 34) . ERCC5:His110Asp is located at the Cterminal end of ERCC5 that is a conserved domain and is required for interactions with other interacting proteins in the incision complex of DNA repair pathways (35) . Therefore, an amino acid changes from basic His to acidic Asp could alter the binding to other proteins in the incision complex of DNA repair pathways and could change the outcome of head and neck cancer. MMP3 is involved in cell adhesion, proliferation, and migration. In an oral SCC cell lines, MMP3 appeared to be necessary for anchorage-independent growth (36) . The deletion or the insertion of an adenine at position À1612 (MMP3:À1612insA) defined two alleles 5A or 6A. The 6A allele is associated with low transcription levels (37) . Moreover, in transgenic mice model, enhanced MMP3 expression facilitates mammary tumor promotion, suggesting that MMP3 is involved in the early steps of carcinogenesis (38) . Thus, a functional interaction of MMP3 with other gene could change the head and neck cancer outcome in some patients. ERCC2 is a DNA helicase involved in nucleotide excision repair (NER) and is an integral member of the basal transcription (39) . The NER genes are the major DNA repair pathway for the removal of bulky DNA lesions. A metaanalysis found a slight increase in cancer risk when carrying the Gln variant allele of ERCC2 (40) . We found that the Gln variant allele of ERCC2:Lys751Gln was associated with improved DFS when compared with the wild-type Lys/Lys, compatible with one other study (41) that focused on cisplatin-treated patients (with or without radiation). Previous studies showed the variant Gln allele was associated with lower DNA repair capacity (42) . Because all of our patients underwent radiation, a DNA repair-radiotherapy interaction could explain these results, whereby individuals with lower DNA repair capacity had tumors that were also similarly predisposed, and thus were more susceptible to radiotherapy-induced DNA damage. Further biologic assessments are necessary to test this theory. As we found that ERCC2:Lys751Gln interacts with XPA:5 0 UTR, a possible explanation is that this interaction, if biologically mediated, is because XPA binds to damaged DNA and facilitates repair complex assembly, subsequently leading to ERCC2 catalyzing 5 0 and 3 0 -incision, which stabilizes the repair complex (43) .
TP53, a tumor suppressor gene, shows frequent somatic mutations in human cancers and is commonly associated with a more aggressive tumor phenotype, with worse clinical outcome and with an increased risk for developing cancers (44) . In our study, we found that patients carrying Pro alleles of TP53:Arg72Pro have worse DFS than patients carrying Arg/Arg. The Arg72Pro substitution is located in a proline-rich region of the TP53 protein, where the Pro amino acid is part of 5 PXXP motifs considered to be involved in different cellular function. It has been reported that the Arg exhibits a 15-fold higher apoptosis-inducing ability than the Pro variant. However, the Pro variant results in more cell arresting in the G 1 cell-cycle phase than does the Arg protein variant (45) . It might be possible that the Pro containing protein variant decreased the ability to induce apoptosis, leading to a worse outcome.
As cancer risk factors are multifactorial that involve both heritable traits (i.e., GSVs) and the accumulation of somatic mutations across different important cellular pathways, these genomic effects can also affect biologic aggressiveness of the resultant cancer, response to therapy (such a radiation), and thereby influence clinical outcome. Elucidating the genetic factors must occur in the context of adjustment or controlling for a number of important prognostic factors, including population heterogeneity or ethnicity, disease stage, treatment, anatomic subtype, and level of tobacco or alcohol exposures, comorbidities, all of which had been shown to potentially contribute to prognosis and could modify disease. In many studies, these factors were never considered (or data were never collected). Combined with the publication bias toward positive association studies (46) , the potential for false-positive published findings is great. Furthermore, some sequence variants might simply be in linkage disequilibrium with other more functional sequence variants. In recent years, oncogenic HPV, in particular HPV16, has been found to be associated with head and neck cancer with increased survival compared with non-HPV head and neck cancer (5, 47) . The association varies in different head and neck cancer sites, with the highest and recently rising rates in oropharyngeal cancer, followed by hypopharynx (13%-25%), oral cavity (12%-18%), and lowest prevalence in laryngeal cancer (3%-7%; ref. 48 ). More than 80% of our patients were laryngeal cancer patients, whereas only 5% were pharyngeal; all were recruited more than a decade ago. Thus, our population would not be significantly impacted by HPV. In addition, tissue was not available for HPV analysis.
There are limitations in this study. Our early-stage cancers had fewer events than other studies with higher stage disease; the lower numbers reduces power for the same number of patients. We also had a laryngeal cancer predominant population; generalization to all HNSCCs may not be possible. For DFS, the nominally significant relationships are unlikely to translate into clinical relevance. Our early-stage patients are rarely treated with chemotherapy; thus, predictors of chemotherapeutic pharmacokinetic factors are not evaluable.
All candidate-based polymorphism studies suffer from the potential for missing significant associations. We defined our set of sequence variants of interest, based on our review of the literature (6), but the literature changes over time. For example, Bergmann and colleagues recently found that genetic polymorphisms in toll-like receptor 4 (TLR4) may serve as markers for prognosis of head and neck cancers (49) . We aim to conduct additional validation studies in the future, as research in this field grows.
In conclusion, our study did not validate the sequence variants for OS but actually suggested that 2 variants (CTLA4:A49G and XRCC1:Arg339Gln) may actually be associated with OS in the opposite direction. Modest relationships of head and neck cancer DFS with ERCC2: Lys751Gln and TP53:Arg72Pro sequence variants cannot be excluded. Given the lack of replication of the majority of sequence variants in this validation study, future analyses of head and neck cancer sequence variants with outcome should consider discovery and validation multistep approaches, in connection with comprehensive pathway or genome-wide agnostic polymorphism selection approaches.
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